Kara Lefevre, MD
Dermatopathology · Columbia, MONPI 1164620670
Payments from drug & device makers
What this record shows
This record is dominated by education: $159 of the $193 with a category attached, or 82.5%. 3 manufacturers reported payments, led by Lilly USA, LLC at 51.4% of the total.
Across 4 payments — averaging $48.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$99
- Johnson & Johnson$60
- AbbVie$34
Across 38 payments — averaging $8092.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$296K
- Boehringer Ingelheim Pharma GmbH & Co.kg$9K
- Boehringer Ingelheim RCV GmbH & Co KG$2K
What the payments were for
- Food & beverage$3417%
- Education$15983%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1 | $99 |
| Johnson & Johnson | 1 | $60 |
| AbbVie | 2 | $34 |
How this compares
Too few dermatopathology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 16 | $347,974 |
| StelaraUstekinumab | 14 | $272,387 |
| TremfyaGuselkumab | 20 | $266,729 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 32 | $235,870 |
| Humira PenAdalimumab | 15 | $95,357 |
| Dupixent SyringeDupilumab | 12 | $46,073 |
| Dupixent PenDupilumab | 11 | $40,791 |
| XolairOmalizumab | 11 | $29,899 |
| Hydroxychloroquine Sulfate | 22 | $1,587 |
| Doxycycline Hyclate | 16 | $849 |
| Doxepin Hcl | 15 | $694 |
| Tretinoin | 14 | $663 |
| Clobetasol Propionate | 14 | $385 |
| MethotrexateMethotrexate Sodium | 11 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Tremfya | $60 | $539,11534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in Missourion file to place this against a meaningful peer group, so we don't.
Other dermatopathology in Columbia
- M Yadira HurleySaint Louis$12K
- Georgeanne CornellSaint Louis$3K
- Emily SmithSaint Louis$3K
- Mark HurtMaryland Heights$2K
- Sarah WalshMaryland Heights$1K
- Kristine SmithSaint Louis$133
- William BlankChaffee$28
- Cecilia RosalesKansas City$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.